Yi Xu

Yi Xu

Auto-generated profile, based on publicly available information

Yi Xu

Department of Cardiology, Ningbo First Hospital, Ningbo, China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2022 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
DCDelong Chen
Delong Chen
YZYuxuan Zhang
Yuxuan Zhang
AYAbuduwufuer Yidilisi
Abuduwufuer Yidilisi
YXYi Xu
Yi Xu
QDQichao Dong
Qichao Dong
JJJun Jiang
Jun Jiang
Context Observational studies have suggested associations between adipokines and cardiovascular disease (CVD), but the roles of certain adipokines remain controversial, and these associations have not yet been ascertained causally. Objective To investigate whether circulating adipokines causally affect the risk of CVD using 2-sample Mendelian randomization (MR). Methods Independent genetic variants strongly associated with adiponectin, resistin, chemerin, and retinol binding protein 4 (RBP4) were selected from public genome-wide association studies. Summary-level statistics for CVD, including coronary artery disease (CAD), myocardial infarction, atrial fibrillation (AF), heart failure (HF), and stroke and its subtypes were collected. The inverse-variance weighted and Wald ratio methods were used for the MR estimates. The MR pleiotropy residual sum and outlier, weighted median, MR-Egger, leave-one-out analysis, MR Steiger, and colocalization analyses were used in the sensitivity analysis. Results Genetically predicted resistin levels were positively associated with AF risk (odds ratio [OR] 1.09; 95% confidence interval [CI], 1.04-1.13; P = 4.1 × 10-5), which was attenuated to null after adjusting for blood pressure. We observed suggestive associations between higher genetically predicted chemerin levels and an increased risk of CAD (OR 1.27; 95% CI, 1.01-1.60; P = 0.040), higher genetically predicted RBP4 levels and an increased risk of HF (OR 1.14; 95% CI, 1.02-1.27; P = 0.024). There was no causal association between genetically predicted adiponectin levels and CVD risk. Conclusions Our findings reveal the causal association between resistin and AF, probably acting through blood pressure, and suggest potential causal associations between chemerin and CAD, RBP4, and HF.

12 November 2012 in European Journal of Trauma and Emergency Surgery
Verified
Journal Article
Closed access
PDF file
YXY. Xu
Y. Xu
HLH. Li
H. Li
HYH.-H. Yang
H.-H. Yang

27 December 2022 in Journal of Interventional Cardiology
Verified
Journal Article
Open access
PDF file
YZYuxuan Zhang
Yuxuan Zhang
DCDelong Chen
Delong Chen
QDQichao Dong
Qichao Dong
YXYi Xu
Yi Xu
JFJiacheng Fang
Jiacheng Fang
JJJun Jiang
Jun Jiang
Background. The role of a drug-coated balloon (DCB) in the treatment of acute myocardial infarction (AMI) is not well established. Methods. Five databases were searched for randomized controlled trials that compared DCB with stents in the treatment of AMI from their inception to 30 July 2021. The primary clinical endpoint was major adverse cardiac events (MACEs). Summary estimations were conducted using fixed-effects analysis complemented by several subgroups. The protocol was registered with PROSPERO (https://clinicaltrials.gov/ct2/show/CRD42021272886). Results. A total of 4 randomized controlled trials with 485 patients were included. On routine clinical follow-up, DCB was associated with no difference in the incidence of MACEs compared with control (risk ratio [RR] 0.59 [0.31 to 1.13]; ). DCB was associated with similar MACEs compared with drug-eluting stent and lower MACEs compared with bare-metal stent. There was no difference between DCB and control in terms of all-cause mortality, cardiovascular mortality, stent thrombosis, target lesion revascularization, and minimal lumen diameter during follow-up. However, DCB was associated with a lower incidence of myocardial infarction (RR 0.16 [0.03 to 0.90]; ) and lower late lumen loss (mean difference −0.20 [−0.27 to −0.13]; ). Conclusions. In treatment of patients with AMI, DCB might be a feasible interventional strategy versus control as it associated with comparable clinical outcomes. Future large-volume, well-designed randomized controlled trials to evaluating the role of the DCB in this setting are warranted.

5 May 2021 in Journal of Interventional Cardiology
Verified
Journal Article
Open access
PDF file
YXYi Xu
Yi Xu
YSYimin Shen
Yimin Shen
DCDelong Chen
Delong Chen
PZPengfei Zhao
Pengfei Zhao
JJJun Jiang
Jun Jiang
Introduction. This network meta-analysis aimed to evaluate the efficacy and safety of different dual antiplatelet therapies (DAPTs) after percutaneous coronary intervention (PCI) with drug-eluting stents (DESs). Methods. Randomized controlled trials (RCTs) comparing longer-term (>12 months) DAPT (L-DAPT), 12-month DAPT (DAPT 12Mo), 6-month DAPT (DAPT 6Mo), 3-month DAPT followed by aspirin monotherapy (DAPT 3Mo+ASA), 3-month DAPT followed by a P2Y12 receptor inhibitor monotherapy (DAPT 3Mo+P2Y12), or 1-month DAPT with a P2Y12 receptor inhibitor monotherapy (DAPT 1Mo+P2Y12) were searched. Primary endpoints were all-cause mortality, cardiac death, myocardial infarction (MI), major bleeding, any bleeding, definite or probable stent thrombosis (ST), and net adverse clinical events (NACE). This Bayesian network meta-analysis was performed with the random-effects model. Results. Twenty-four RCTs (n=81339) were included. In comparison with L-DAPT, DAPT 6Mo (OR: 0.50, 95 CI: 0.290.83), DAPT 3Mo+P2Y12 (OR: 0.38, 95 CI: 0.180.82), DAPT 3Mo+ASA (OR: 0.44, 95 CI: 0.170.98), and DAPT 1Mo+P2Y12 (OR: 0.45, 95 CI: 0.140.93) were associated with a lower risk of major bleeding. DAPT 3Mo+P2Y12 (OR: 0.58, 95 CI: 0.380.88) reduced the risk of any bleeding when compared with DAPT 12Mo. L-DAPT decreased the risk of MI and definite or probable stent ST when compared with DAPT 6Mo. DAPT 3Mo+P2Y12 decreased the risk of NACE in comparison with DAPT 6Mo and DAPT 12Mo. No significant difference in all-cause mortality and cardiac death was observed. In patients with acute coronary syndrome, DAPT 6Mo was comparable to DAPT 12Mo. Conclusion. Short-term (13 months) DAPT is noninferior to DAPT 6Mo after DESs implantation, while L-DAPT reduces MI and definite or probable ST rates. DAPT 3Mo+P2Y12 might be a reasonable trade-off in patients with high risk of bleeding accompanied by ischemia.

Verified
Journal Article
Open access
PDF file
Guohua FuGuohua Fu
Guohua Fu
BHBin He
Bin He
Binhao WangBinhao Wang
Binhao Wang
MFMingjun Feng
Mingjun Feng
XDXianfeng Du
Xianfeng Du
HCHuimin Chu
Huimin Chu
Background: This research explores the relationship between the unipolar electrogram (UP-EGM) and lesion size index (LSI) in different regions of continuous circular lesions (CCLs) and to assess the safety and efficacy of UP-EGM-guided versus LSI-guided radiofrequency catheter ablation (RFCA) in patients with paroxysmal atrial fibrillation (PAF). Methods: A total of 120 patients with drug-refractory PAF who underwent index RFCA were scheduled to be consecutively included from March 2020 to April 2021. All the patients were randomly divided 1:1 into two groups: the UP-EGM group and the LSI group. The first-pass PVI rate, acute PVI rate, and the sinus rhythm maintenance rate were compared. Results: A total of 120 patients with PAF were included in the study: the UP-EGM group (n = 60) and the LSI group (n = 60). All the LSI values in the UP-EGM group were less than those in the corresponding regions in the LSI group (all p < 0.001). There were no significant differences in the first-pass PVI rate and acute PVI rate between the two groups. After a mean follow-up period of 11.31 ± 1.70 months, the sinus rhythm maintenance rate in the UP-EGM group was comparable to that in the LSI group (90% vs. 91.7%, p = 0.752). Conclusion: UP-EGM-guided and LSI-guided RFCA are both effective and safe in patients with PAF. However, UP-EGM may be more suitable than LSI for guiding individual RFCA.

30 May 2023 in Genetic Testing and Molecular Biomarkers
Verified
Journal Article
Closed access
SGSiyuan Guo
Siyuan Guo
ZZZuo Zhou
Zuo Zhou
Tingting GuoTingting Guo
Tingting Guo
YXYi Xu
Yi Xu
XYXintao Yang
Xintao Yang
RCRenji Chen
Renji Chen
Background: Nonsyndromic cleft lip with or without cleft palate (NSCL/P) is a complex congenital disease affected by genetic and environmental factors however, the specific pathogenic alleles and regulatory mechanisms remain unclear in many cases. Here, we aimed to study the association between eight potentially functional single nucleotide polymorphisms (SNPs) of the BRCA2 and MGMT genes and NSCL/P in a Chinese population through a case-control study. Materials and Methods: To investigate the relationship between potentially functional SNPs of the BRCA2 and MGMT genes and NSCL/P, we selected 200 affected patients and 200 unrelated normal controls in a Chinese population. The BRCA2 gene SNPs (rs11571836, rs144848, rs7334543, rs15869, rs766173 and rs206118) and MGMT gene SNPs (rs12917 and rs7896488) were genotyped using the SNaPshot technique and the resulting data were subjected to statistical and bioinformatic analyses. Results: Our study identified for the first time that alleles of the BRCA2 are associated with NSCL/P in a Chinese population and that the s11571836 G allele was protective against NSCL/P. Under four genetic models, rs11571836 had a significant correlation with NSCL/P. Preliminary bioinformatic analyses revealed four potential miRNA matching sites (miR-1244, miR-1323, miR-562, and miR-633) associated with the rs11571836 which is located in the 3′ untranslated region of BRCA2 . Conclusions: These results support the role of polymorphisms of BRCA2 gene in affecting susceptibility to NSCL/P and its progression, but further research is necessary to elucidate the mechanism by which the BRCA2 gene polymorphisms affect the penetrance of NSCL/P.